Latest Franking News

Vita Life Sciences delivered a robust first half in 2026 with revenue up 6.1% to A$48.3 million and net profit after tax rising 14.9% to A$5.54 million. The company declared a higher interim dividend, reflecting improved margins and regional market momentum.

Regal Asian Investments (ASX:RG8) posted a stellar FY26 with a net profit after tax of $124.8 million, driven by a 52.6% net portfolio return and a 10 cent fully franked final dividend, reflecting strong exposure to Asian semiconductors amid the AI boom.

Iress Limited’s half year net profit after tax surged 85% to $32 million, driven by sharp cost cuts and margin expansion, even as total revenue fell nearly 17% following recent divestments.

FFI Holdings grew revenue by 7.4% to $62.76 million in FY2026, yet net profit after tax fell sharply by 51.5% to $3.23 million, reflecting the absence of last year’s $5.19 million property revaluation gain and a 26% drop in rental income due to lease changes.

JB Hi-Fi delivered a solid FY26 with record revenue and profit growth, declaring a 22.5% higher dividend and advancing its net-zero emissions goal.

L1 Group Limited delivered a standout FY26 with statutory profit up 79% and underlying net profit nearly doubling, driven by merger synergies and strong fund performance.

Aurizon lifted FY2026 underlying EBITDA by 9% to $1.72 billion, boosted by strong Bulk growth and regulatory gains, while locking in a major Queensland coal haulage contract with BHP Mitsubishi Alliance.

Fiducian Group posted solid underlying earnings growth in FY2026, boosted by a 7% rise in funds under management, advice and administration, while absorbing a one-off $7.95 million ASIC penalty that halved statutory profits.

oOh!media reported a 1.4% revenue increase to $340.9 million in 1H26 but saw adjusted underlying EBITDA fall 22.5% due to rising fixed rents and soft billboard demand. The company declared a 2 cent interim dividend and agreed to a $1.68 per share takeover scheme with I Squared Capital.

GWA Group posted modest revenue and earnings growth in FY26, driven by volume gains across Australia, New Zealand, and the UK, while raising dividends and advancing strategic priorities despite challenging market conditions.

Australian Clinical Labs (ASX: ACL) delivered a modest 1.7% underlying EBIT increase in FY26, navigating subdued revenue and rising labour costs with operational efficiencies and strategic initiatives.

IMDEX Limited (ASX:IMD) delivered a standout FY26 with 21% revenue growth to $520 million and a 44% jump in net profit to $79 million, driven by organic growth and five key acquisitions. The company raised its dividend and expanded its digital earth science footprint, positioning for further gains.